Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Significant differences were observed among the three groups for several variables, including hypertension, fracture, body mass index (BMI), neutrophil counts, free triiodothyronine (FT3), creatinine (Cr), calcium (Ca), and 25-hydroxy vitamin D [25-(OH) D] (all p < 0.05).
Source: Baseline characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This ambispective longitudinal cohort study utilized multicenter retrospective cohort data collected between January 1, 2014, and January 1, 2016 (Phase 1), followed by prospective follow-up for fragility fracture endpoints from January 1, 2016, to January 1, 2021 (Phase 2).
Source: Abstract.
A total of 423 participants were included in the present analysis.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
HALP score-adjusted FRAXplus tool effectively predicts hip fracture risk in elderly women with type 2 diabetes mellitus
Cohort study · BMC Endocrine Disorders · 2026
Original publication title
HALP score-adjusted FRAXplus tool effectively predicts hip fracture risk in elderly women with type 2 diabetes mellitus
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Elderly women with type 2 diabetes mellitus (T2DM) are at high risk of fragility fractures, particularly lethal hip fractures. Pathophysiologically, this elevated risk may be attributed to reduced nutritional reserves and dysregulation of the immune-inflammatory system. However, the fracture risk assessment tool (FRAX) often underestimates the 10-year probability of future fractures, as it does not fully account for these pathophysiological factors in this high-risk population. This study aims to determine whether the hemoglobin, albumin, lymphocyte, and platelet (HALP) score serves as an effective prognostic marker for a real-world fragility fracture endpoint, and whether incorporating the HALP score into FRAX improves the prediction of the 10-year probability of fragility fractures in this high-risk population.
Source: BackgroundAbstract: What methods does the paper describe?
This ambispective longitudinal cohort study utilized multicenter retrospective cohort data collected between January 1, 2014, and January 1, 2016 (Phase 1), followed by prospective follow-up for fragility fracture endpoints from January 1, 2016, to January 1, 2021 (Phase 2). Follow-up was conducted via outpatient services and telephone interviews every six months, with a median follow-up duration of 46.8 months. A total of 423 participants were included in the present analysis. Based on HALP score tertiles, participants were divided into low (≤ 31.98, n = 141), moderate (31.98 to 48.08, n = 140), and high (≥ 48.08, n = 142) groups.
Source: MethodsAbstract: Results
Among the 423 participants, 75 (17.73%) experienced real-world fragility fractures. Spearman’s partial correlation analysis revealed a significant inverse association between the HALP score and the FRAX‑estimated 10‑year probability of hip fracture (FRAX‑HF) (r = − 0.103, p = 0.037), but no significant correlations with bone mineral density (BMD) and the FRAX‑estimated 10‑year probability of major osteoporotic fracture (FRAX‑MOF). Multivariate linear regression further quantified that each one‑tertile decrease in HALP (tertile interval = 16.1) was associated with an approximate 0.31% increase in FRAX‑HF probability (calculated as 0.019 × 16.1 = 0.3059) (β = −0.019; 95% confidence interval [CI]: −0.034 to − 0.005; p = 0.007).
Notably, in the lowest HALP tertile, the FRAX‑HF increased from the overall baseline of 2.30% (moderate risk, requiring only lifestyle management) to 3.00% (high risk, warranting anti‑osteoporosis therapy), representing a relative increase of 30.43%. Consequently, all non‑osteoporotic participants in this tertile, whose initial hip fracture probability (2.3%) was below the guideline-recommended intervention threshold of 3%, met criteria for initiating anti‑osteoporosis treatment, resulting in an intervention rate of 27.13% (35/129). These findings support the utility of combining the HALP score with FRAX for risk stratification to refine hip fracture prediction.
Restricted cubic spline (RCS) analysis indicated dose‑dependent nonlinear relationships between HALP and overall fragility fracture endpoint events (Z‑shaped, overall p = 0.0011), as well as between HALP and FRAX‑HF (L‑shaped, overall p < 0.001). Multivariable Cox regression confirmed a significant inverse trend between HALP and the real‑world fragility fracture endpoint (p for trend = 0.002), and subgroup stratified analyses demonstrated stable predictive value across strata (all p for interaction > 0.05). Kaplan: Meier analysis illustrated a higher cumulative fracture incidence associated with lower HALP scores (log‑rank test, p = 0.00037).
Receiver operating characteristic (ROC) curve analysis identified an optimal HALP cut‑off of 46.77 for fragility fractures, with an area under the curve (AUC) of 0.643 and a sensitivity of 84.0% (p < 0.001).
Source: ResultsAbstract: Conclusion
Our findings suggest that the HALP score may serve as an effective prognostic indicator for fragility fractures. Furthermore, the HALP score-adjusted FRAXplus tool (integrating the HALP score into FRAX) makes more elderly female patients with T2DM whose initial hip fracture probability falls below the guideline-recommended intervention threshold eligible for anti-osteoporosis therapy, thereby helping to reduce future 10-year hip fracture events.
Source: ConclusionAuthors’ abstract
Background
Elderly women with type 2 diabetes mellitus (T2DM) are at high risk of fragility fractures, particularly lethal hip fractures. Pathophysiologically, this elevated risk may be attributed to reduced nutritional reserves and dysregulation of the immune-inflammatory system. However, the fracture risk assessment tool (FRAX) often underestimates the 10-year probability of future fractures, as it does not fully account for these pathophysiological factors in this high-risk population. This study aims to determine whether the hemoglobin, albumin, lymphocyte, and platelet (HALP) score serves as an effective prognostic marker for a real-world fragility fracture endpoint, and whether incorporating the HALP score into FRAX improves the prediction of the 10-year probability of fragility fractures in this high-risk population.
Methods
This ambispective longitudinal cohort study utilized multicenter retrospective cohort data collected between January 1, 2014, and January 1, 2016 (Phase 1), followed by prospective follow-up for fragility fracture endpoints from January 1, 2016, to January 1, 2021 (Phase 2). Follow-up was conducted via outpatient services and telephone interviews every six months, with a median follow-up duration of 46.8 months. A total of 423 participants were included in the present analysis. Based on HALP score tertiles, participants were divided into low (≤ 31.98, n = 141), moderate (31.98 to 48.08, n = 140), and high (≥ 48.08, n = 142) groups.
Results
Among the 423 participants, 75 (17.73%) experienced real-world fragility fractures. Spearman’s partial correlation analysis revealed a significant inverse association between the HALP score and the FRAX‑estimated 10‑year probability of hip fracture (FRAX‑HF) (r = − 0.103, p = 0.037), but no significant correlations with bone mineral density (BMD) and the FRAX‑estimated 10‑year probability of major osteoporotic fracture (FRAX‑MOF). Multivariate linear regression further quantified that each one‑tertile decrease in HALP (tertile interval = 16.1) was associated with an approximate 0.31% increase in FRAX‑HF probability (calculated as 0.019 × 16.1 = 0.3059) (β = −0.019; 95% confidence interval [CI]: −0.034 to − 0.005; p = 0.007).
Notably, in the lowest HALP tertile, the FRAX‑HF increased from the overall baseline of 2.30% (moderate risk, requiring only lifestyle management) to 3.00% (high risk, warranting anti‑osteoporosis therapy), representing a relative increase of 30.43%. Consequently, all non‑osteoporotic participants in this tertile, whose initial hip fracture probability (2.3%) was below the guideline-recommended intervention threshold of 3%, met criteria for initiating anti‑osteoporosis treatment, resulting in an intervention rate of 27.13% (35/129). These findings support the utility of combining the HALP score with FRAX for risk stratification to refine hip fracture prediction.
Restricted cubic spline (RCS) analysis indicated dose‑dependent nonlinear relationships between HALP and overall fragility fracture endpoint events (Z‑shaped, overall p = 0.0011), as well as between HALP and FRAX‑HF (L‑shaped, overall p < 0.001). Multivariable Cox regression confirmed a significant inverse trend between HALP and the real‑world fragility fracture endpoint (p for trend = 0.002), and subgroup stratified analyses demonstrated stable predictive value across strata (all p for interaction > 0.05). Kaplan: Meier analysis illustrated a higher cumulative fracture incidence associated with lower HALP scores (log‑rank test, p = 0.00037).
Receiver operating characteristic (ROC) curve analysis identified an optimal HALP cut‑off of 46.77 for fragility fractures, with an area under the curve (AUC) of 0.643 and a sensitivity of 84.0% (p < 0.001).
Conclusion
Our findings suggest that the HALP score may serve as an effective prognostic indicator for fragility fractures. Furthermore, the HALP score-adjusted FRAXplus tool (integrating the HALP score into FRAX) makes more elderly female patients with T2DM whose initial hip fracture probability falls below the guideline-recommended intervention threshold eligible for anti-osteoporosis therapy, thereby helping to reduce future 10-year hip fracture events.
Clinical trial number
Not applicable.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12902-026-02338-3.
Publication and source details
Original title: HALP score-adjusted FRAXplus tool effectively predicts hip fracture risk in elderly women with type 2 diabetes mellitus
Wenxin Chu; Minghui Wu; Jingxia Sun; Jiangmei Pan; Zhengming Li; Jianhao Huang; Zhenwei Zhai; Wensheng Lu
BMC Endocrine Disorders · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.the Self-funded Scientific Research Project of the Health Commission of Guangxi Zhuang Autonomous RegionNo. Z-A20240099No. Z-A20240116Sun Jingxia Zhai ZhenweiRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:22:27.061179+00:00
DOI: 10.1186/s12902-026-02338-3 · PMC13455395